For US brands evaluating cross-border into Asia, the three biggest markets — Korea, Japan, and China — get treated as if they share a common opportunity. They don’t. The de minimis frameworks differ structurally, the regulatory carve-outs differ by category, and the policy outlook over the next 24-36 months is meaningfully different in each.
This piece is an honest read on which US-origin product categories win in which Asian markets in 2026, and which categories carry the most risk as the policy environment continues to evolve.
The three frameworks, briefly
Before category analysis, a quick frame on how the three markets actually treat low-value imports — because they’re not the same thing.
Korea operates the most accommodating de minimis regime for US-origin goods anywhere in Asia. Under KORUS, US-origin shipments under $200 enter duty-free and VAT-free, with simplified customs. This is treaty-anchored and durable. Non-US-origin goods get a $150 threshold, giving US brands a structural 33% headroom advantage.
Japan operates a much tighter regime. The JPY 10,000 (~$65 USD) de minimis is functional today but actively being dismantled. The Ministry of Finance passed legislation in March 2026 abolishing the 0.6x personal-use valuation rule effective April 2028, and the working group is reviewing whether to eliminate the threshold entirely. Operators should treat Japan’s current de minimis as a closing window.
China doesn’t run a traditional de minimis. Instead, it operates a Cross-Border E-Commerce (CBEC) framework with RMB 5,000 (~$725 USD) per-transaction and RMB 26,000 (~$3,780 USD) annual personal limits, plus a 1,476-item positive list gating eligible categories. Qualifying CBEC purchases get 0% duty and 70% of VAT/consumption tax — meaningfully better than general trade. The framework is durable but bureaucratic.
That structural difference shapes everything that follows.
Korea: the cross-border market most US CPG brands should prioritize
Korea is the easiest cross-border Asian market for most US CPG categories, full stop. The KORUS regime, the cross-border platform infrastructure (Coupang Rocket Direct, iHerb Korea), and the Korean consumer’s deep trust in US-origin functional CPG combine into a genuinely accommodating environment.
Dietary supplements are the strongest category fit in Korea. US-origin functions as a category-level quality signal for Korean consumers, regulatory friction under personal-import quantities is minimal, AOV typically lands in the $50-180 range that fits well under $200 de minimis, and replenishment economics (60-90 day reorder cycles) align perfectly with cross-border delivery times. Cross-border supplements are roughly 19% of all Korean cross-border GMV — the largest single category.
Beauty and personal care is the second-strongest fit. Korean consumers buying US dermatology-positioned brands (CeraVe-tier and above), specialty skincare, and clean-formulation beauty find iHerb Korea and Coupang Rocket Direct the natural channels. AOV fits comfortably under $200 for most non-luxury price tiers. The competitive density is higher than in supplements — Korean domestic beauty is genuinely strong — but the US-origin premium positioning remains real for clinical and dermatology brands.
Baby and infant care punches above its category size. Korean parents have lived through repeated domestic safety scandals over the last decade and trust US-origin baby formula, infant skincare, and feeding products at premium price points. Regulatory friction is minimal under personal-import quantities. Cross-border channels carry meaningful share for premium US baby brands.
Pet care is an emerging category with structural tailwinds. Korean pet ownership rates have grown substantially, premium pet nutrition demand has followed, and US brands have strong category-level positioning. Cross-border AOV fits well under $200. Competition is still developing — meaningful white space for US brands entering now.
Health foods and specialty grocery is the most variable category. Categories like premium nut butters, specialty snacks, sports nutrition foods, and clean-label functional foods work well for US brands. Categories that compete directly against established Korean domestic equivalents (instant coffee, snack foods, beverages) struggle. The trick is identifying which US-origin food positions as premium-functional rather than commodity.
Korea outlook 24-36 months: Stable. KORUS is treaty-anchored and not on any current renegotiation agenda. The structural advantages for US-origin CPG persist. Categories that work today will keep working.
Japan: a closing window for US-origin CPG
Japan is structurally a meaningful cross-border market — wealthy consumers, high CPG spend per capita, established preference for US-origin in several functional categories — but operators should approach it with awareness that the current de minimis environment is actively being dismantled.
Supplements and sports nutrition remain a strong category fit for Japan. US-origin trust is real, particularly for sports nutrition, weight management, and functional supplements. The JPY 10,000 threshold accommodates single-unit AOV well for most product types. iHerb is the dominant cross-border channel; Amazon Japan and Rakuten provide additional surface.
Beauty and personal care has a more nuanced fit. Japanese consumers are loyal to domestic beauty brands at a level Korean consumers aren’t, but US-origin works well in specific niches — clinical dermatology, professional-grade skincare, and clean-formulation positioning aimed at consumers who’ve researched outside Japanese brand defaults. AOV constraints under the JPY 10,000 threshold limit single-purchase basket sizes, which favors smaller-format SKUs.
Pet care is a steadily growing category. Japanese pet ownership trends mirror Korea’s, US-origin premium nutrition has a real audience, and the regulatory environment is accommodating. The category is still under-penetrated by US brands.
Health foods can work but is heavily category-specific. Premium specialty foods, functional beverages, and sports nutrition foods find buyers. Mass-market food categories lose to Japanese domestic options.
Baby and infant is structurally harder in Japan than in Korea. Japanese consumers have stronger trust in domestic baby brands and the regulatory environment for cross-border baby products is more constrained.
Japan outlook 24-36 months: Compressing. The March 2026 legislation eliminating the 0.6x personal-use valuation rule effective April 2028 is a meaningful tightening. The Ministry of Finance working group reviewing further reforms to the JPY 10,000 threshold itself raises the realistic probability of further compression within the next 24 months. Brands entering Japan cross-border today should price unit economics assuming further policy compression. The current window is real, but it’s not durable.
China: a different game entirely
China cross-border via CBEC isn’t really comparable to Korea or Japan — the architecture, the platforms, the operational requirements, and the economics are different enough that brands should treat it as a separate strategic decision.
Supplements and health products are one of the strongest CBEC categories. Chinese consumer trust in US-origin supplements is exceptionally strong, AOV regularly exceeds $100 (which works fine under CBEC’s higher personal-import limits), and the CBEC framework lets brands skip much of the NMPA registration that would otherwise gate general-trade entry. Tmall Global and JD Worldwide are the dominant platforms.
Beauty and personal care is the most-cited CBEC win story. CBEC lets brands skip China’s lengthy NMPA cosmetics registration — by far the largest regulatory barrier to traditional China entry. Premium US skincare, clinical dermatology, and clean-formulation beauty find substantial demand. AOV is meaningful (Chinese cross-border beauty AOVs frequently run $80-200+), and the CBEC framework supports the premium positioning. This is the category where China cross-border most justifies the operational complexity.
Baby and infant is one of the largest CBEC categories. Chinese parents’ demand for US-origin baby formula, infant care, and feeding products is well-documented and durable, particularly post-2008 melamine scandal. CBEC lets brands serve this demand without traditional general-trade infant formula registration.
Pet care is rapidly growing as Chinese pet ownership expands. US premium pet nutrition has strong CBEC-channel viability.
Health foods is a meaningful but selective category — functional foods, premium specialty grocery, and supplement-adjacent food products work; commodity foods don’t.
China outlook 24-36 months: Structurally durable but operationally complex. CBEC has been politically supported through multiple Chinese government cycles and continues to expand (CBEC trade grew 15.5% in 2025). The framework is not at risk of disappearing. The actual challenges are operational — choosing the right platform (Tmall Global vs. JD Worldwide vs. Kaola), managing bonded warehouse logistics, navigating positive-list category eligibility, and absorbing the marketing investment required to win on Chinese cross-border platforms.
What this means strategically
For US CPG brands evaluating Asian cross-border in 2026:
Korea is the highest-probability cross-border market in Asia for US-origin CPG. The structural advantages compound (KORUS de minimis, US-origin trust, mature cross-border platform infrastructure, replenishment-friendly AOVs). Brands with category fit in supplements, beauty, baby, pet, or specialty health foods should lead with Korea.
Japan is a meaningful market but a closing window. Brands that can launch within the next 12-18 months capture a real opportunity. Brands that wait until 2028 may find the economics no longer support cross-border at the same scale. The category fit is narrower than Korea — supplements, pet, and specific niches in beauty and health foods are the strongest.
China is its own strategic decision. CBEC is a different operational model than traditional cross-border, the platform investment requirement is higher, but the regulatory carve-outs (especially for beauty and baby) create entry advantages that don’t exist in any other major Asian market. For brands with the operational capacity, the upside is meaningful.
The category pattern is consistent across all three markets. Supplements, beauty (clinical/dermatology positioning), baby, pet, and premium health foods are the structurally favored US-origin categories in Asian cross-border. Apparel, electronics, mass-market food, and commodity consumer goods are not. The closer your category is to “functional CPG with US-origin trust signal and replenishment economics,” the better it works in every Asian market that has any form of cross-border accommodation.
The brands that will look back in three years and credit themselves with good timing on Asian cross-border are the ones launching the right categories into the right markets in 2026 — Korea broadly, Japan tactically and quickly, and China for brands willing to commit to CBEC operational complexity. The brands that miss are the ones who treated “Asian cross-border” as one decision instead of three.
See your category before you commit to a market
The structural argument above only gets you to the door. Once you’re inside, you need to know which competitors are winning in your category in each market, where pricing is trending, and which SKUs are breaking out — and that data has historically been unavailable for the Asian cross-border platforms.
Factum K tracks every brand and SKU across Coupang and iHerb Korea daily, with expanding coverage across other Asian cross-border platforms. For brands evaluating Korean, Japanese, or Chinese cross-border entry, Signal gives you the same visibility the leading operators have.
We’ll pull live data on your category and walk through which market makes most sense for your specific brand profile.
Factum K is the data and intelligence platform for global brands selling on cross-border marketplaces. Live at factumk.com.